---
title: "Clinical Biochemistry"
order: 3
category: "Biochemistry"
---

# Clinical Biochemistry

## Overview

Clinical biochemistry involves the analysis of blood, urine, and other body fluids to assess health status, diagnose disease, monitor treatment, and evaluate prognosis. It bridges basic biochemistry with clinical medicine, providing quantitative data essential for patient care.

### Key Concepts
- **Reference ranges**: Normal values for healthy populations
- **Analytical variation**: Technical factors affecting test results
- **Biological variation**: Natural fluctuations in body chemistry
- **Clinical correlation**: Interpreting results in clinical context

## Glucose Metabolism

### Normal Glucose Homeostasis
- **Fasting glucose**: 70-100 mg/dL (3.9-5.6 mmol/L)
- **Random glucose**: <200 mg/dL (11.1 mmol/L)
- **2-hour OGTT**: <140 mg/dL (7.8 mmol/L)
- **HbA1c**: <5.7% (39 mmol/mol)

### Diabetes Mellitus Criteria
- **Fasting glucose**: ≥126 mg/dL (7.0 mmol/L)
- **2-hour OGTT**: ≥200 mg/dL (11.1 mmol/L)
- **Random glucose**: ≥200 mg/dL with symptoms
- **HbA1c**: ≥ 6.5% (48 mmol/mol)

### Glucose Monitoring
- **HbA1c**: 2-3 month average glucose control
- **Fructosamine**: 2-3 week average (shorter term than HbA1c)
- **Continuous glucose monitoring**: Real-time glucose trends

## Lipid Metabolism

### Lipid Profile Components
- **Total cholesterol**: <200 mg/dL (5.2 mmol/L) desirable
- **LDL cholesterol**: <100 mg/dL (2.6 mmol/L) optimal
- **HDL cholesterol**: >40 mg/dL men, >50 mg/dL women
- **Triglycerides**: <150 mg/dL (1.7 mmol/L)

### Cardiovascular Risk Assessment
- **Non-HDL cholesterol**: Total cholesterol - HDL cholesterol
- **Apolipoprotein B**: Better predictor than LDL cholesterol
- **Lipoprotein(a)**: Independent cardiovascular risk factor
- **Small dense LDL**: More atherogenic than large LDL

### Lipid Disorders
- **Familial hypercholesterolemia**: LDL receptor defects
- **Hypertriglyceridemia**: >500 mg/dL increases pancreatitis risk
- **Low HDL**: <40 mg/dL increases cardiovascular risk

## Protein Metabolism

### Protein Assessment
- **Total protein**: 6.0-8.3 g/dL (60-83 g/L)
- **Albumin**: 3.5-5.0 g/dL (35-50 g/L)
- **Globulins**: 2.0-3.5 g/dL (20-35 g/L)
- **A/G ratio**: 1.2-2.2

### Albumin Functions
- **Oncotic pressure**: Maintains intravascular volume
- **Transport**: Binds drugs, hormones, fatty acids
- **Antioxidant**: Scavenges free radicals
- **Half-life**: 20 days (reflects chronic nutritional status)

### Protein Electrophoresis
- **Albumin**: Largest fraction (55-65%)
- **α1-globulin**: Acute phase proteins
- **α2-globulin**: Haptoglobin, transferrin
- **β-globulin**: Complement, transferrin
- **γ-globulin**: Immunoglobulins

## Liver Function Tests

### Hepatocellular Injury
- **ALT (alanine aminotransferase)**: 7-56 U/L, liver-specific
- **AST (aspartate aminotransferase)**: 10-40 U/L, less specific
- **AST/ALT ratio**: >2 suggests alcoholic liver disease

### Cholestatic Injury
- **Alkaline phosphatase**: 44-147 U/L, bile duct obstruction
- **GGT (γ-glutamyl transferase)**: 9-48 U/L, confirms hepatic origin
- **Direct bilirubin**: >0.3 mg/dL suggests conjugated hyperbilirubinemia

### Synthetic Function
- **Albumin**: Decreased in chronic liver disease
- **Prothrombin time**: Prolonged in acute liver failure
- **Factor V**: Short half-life, acute liver function marker

### Bilirubin Metabolism
- **Total bilirubin**: 0.3-1.2 mg/dL (5-21 μmol/L)
- **Direct (conjugated)**: 0.0-0.3 mg/dL (0-5 μmol/L)
- **Indirect (unconjugated)**: 0.2-0.8 mg/dL (3-14 μmol/L)

## Kidney Function Tests

### Glomerular Filtration
- **Creatinine**: 0.6-1.2 mg/dL (53-106 μmol/L)
- **eGFR**: >90 mL/min/1.73m² normal
- **BUN**: 7-20 mg/dL (2.5-7.1 mmol/L)
- **BUN/creatinine ratio**: 10-20 (normal)

### GFR Estimation
- **MDRD equation**: Uses creatinine, age, sex, race
- **CKD-EPI equation**: More accurate at higher GFR
- **Cystatin C**: Alternative marker, less muscle mass dependent

### Proteinuria
- **Microalbuminuria**: 30-300 mg/g creatinine
- **Proteinuria**: >300 mg/g creatinine
- **Protein/creatinine ratio**: Random urine collection

## Electrolyte Balance

### Sodium (Na+)
- **Normal range**: 136-145 mEq/L (136-145 mmol/L)
- **Hyponatremia**: <135 mEq/L
- **Hypernatremia**: >145 mEq/L
- **Osmolality**: 280-295 mOsm/kg

### Potassium (K+)
- **Normal range**: 3.5-5.0 mEq/L (3.5-5.0 mmol/L)
- **Hypokalemia**: <3.5 mEq/L
- **Hyperkalemia**: >5.0 mEq/L
- **Critical values**: <2.5 or >6.5 mEq/L

### Chloride (Cl-)
- **Normal range**: 98-107 mEq/L (98-107 mmol/L)
- **Anion gap**: Na+ - (Cl- + HCO3-) = 8-12 mEq/L

## Acid-Base Balance

### Arterial Blood Gas
- **pH**: 7.35-7.45
- **PCO2**: 35-45 mmHg (4.7-6.0 kPa)
- **HCO3-**: 22-26 mEq/L (22-26 mmol/L)
- **Base excess**: -2 to +2 mEq/L

### Acid-Base Disorders
- **Metabolic acidosis**: Low pH, low HCO3-
- **Metabolic alkalosis**: High pH, high HCO3-
- **Respiratory acidosis**: Low pH, high PCO2
- **Respiratory alkalosis**: High pH, low PCO2

## Cardiac Markers

### Troponins
- **Troponin I**: <0.04 ng/mL (highly specific for cardiac injury)
- **Troponin T**: <0.01 ng/mL (alternative to troponin I)
- **High-sensitivity troponin**: Detects lower levels

### Other Cardiac Markers
- **CK-MB**: 0-6.3 ng/mL (less specific than troponin)
- **Myoglobin**: 30-90 ng/mL (early but non-specific)
- **BNP**: <100 pg/mL (heart failure marker)
- **NT-proBNP**: <125 pg/mL (alternative to BNP)

## Thyroid Function

### Thyroid Hormones
- **TSH**: 0.27-4.2 mIU/L (primary screening test)
- **Free T4**: 12-22 pmol/L (0.9-1.7 ng/dL)
- **Free T3**: 3.1-6.8 pmol/L (200-440 pg/dL)
- **Total T4**: 66-181 nmol/L (5.1-14.1 μg/dL)

### Thyroid Antibodies
- **Anti-TPO**: <34 IU/mL (thyroid peroxidase antibodies)
- **Anti-thyroglobulin**: <115 IU/mL
- **TSI**: <140% (thyroid stimulating immunoglobulin)

## Tumor Markers

### Common Tumor Markers
- **PSA**: <4.0 ng/mL (prostate cancer screening)
- **CEA**: <3.0 ng/mL (colorectal cancer monitoring)
- **CA 19-9**: <37 U/mL (pancreatic cancer)
- **CA 125**: <35 U/mL (ovarian cancer)
- **AFP**: <10 ng/mL (hepatocellular carcinoma, testicular cancer)

### Clinical Use
- **Screening**: Limited value due to poor specificity
- **Monitoring**: Treatment response and recurrence detection
- **Prognosis**: Elevated levels may indicate worse prognosis

## Vitamins and Minerals

### Vitamin D
- **25(OH)D**: Total vitamin D status
  - Deficiency: <20 ng/mL (50 nmol/L)
  - Insufficiency: 20-30 ng/mL (50-75 nmol/L)
  - Sufficiency: >30 ng/mL (75 nmol/L)

### Vitamin B12
- **Cobalamin**: 200-900 pg/mL (148-664 pmol/L)
- **Methylmalonic acid**: Elevated in B12 deficiency
- **Homocysteine**: Elevated in B12 and folate deficiency

### Folate
- **Serum folate**: 2.7-17.0 ng/mL (6.1-38.5 nmol/L)
- **RBC folate**: 140-628 ng/mL (317-1422 nmol/L)

### Iron Studies
- **Serum iron**: 60-170 μg/dL (11-30 μmol/L)
- **TIBC**: 250-400 μg/dL (45-72 μmol/L)
- **Transferrin saturation**: 20-50%
- **Ferritin**: 15-150 ng/mL (men), 15-150 ng/mL (women)

## Inflammatory Markers

### Acute Phase Reactants
- **CRP**: <3.0 mg/L (normal), >10 mg/L (acute inflammation)
- **ESR**: <20 mm/hr (men), <30 mm/hr (women)
- **Procalcitonin**: <0.25 ng/mL (bacterial infection marker)

### Complement
- **C3**: 90-180 mg/dL (0.9-1.8 g/L)
- **C4**: 10-40 mg/dL (0.1-0.4 g/L)
- **CH50**: 150-250 U/mL (total complement activity)

## Clinical Applications

### Test Selection
- **Screening tests**: High sensitivity, rule out disease
- **Confirmatory tests**: High specificity, rule in disease
- **Monitoring tests**: Track disease progression or treatment response

### Interpretation Principles
- **Reference ranges**: Consider patient demographics
- **Critical values**: Require immediate clinical attention
- **Trends**: Serial measurements more informative than single values
- **Clinical correlation**: Always interpret in clinical context

### Quality Control
- **Pre-analytical factors**: Sample collection, handling, storage
- **Analytical factors**: Instrument calibration, reagent quality
- **Post-analytical factors**: Result reporting, interpretation

## Key Points

- Clinical biochemistry provides objective data for medical decision-making
- Reference ranges must be interpreted in context of patient demographics and clinical condition
- Trending values over time is often more informative than single measurements
- Glucose and HbA1c are essential for diabetes diagnosis and monitoring
- Lipid profiles guide cardiovascular risk assessment and treatment
- Liver function tests differentiate hepatocellular from cholestatic injury
- Kidney function assessment includes creatinine, eGFR, and proteinuria
- Cardiac troponins are highly specific and sensitive for myocardial injury
- Thyroid function testing uses TSH as primary screening with free T4 for confirmation
- Quality assurance is critical for reliable and accurate test results

## References

1. Burtis CA, Ashwood ER, Bruns DE. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2017.
2. McPherson RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 23rd ed. Elsevier; 2016.
3. Rifai N, Horvath AR, Wittwer CT. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2017.